Recent Updates
Recently added Catalysts
PTCT Positive Sentiment

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 17, 2024, the company approved non-statutory stock options to purchase an...

Key Takeaway: PTC Therapeutics, Inc. has announced that on June 17, 2024, it approved stock options and restricted stock units (RSUs) for nine new hires as part of their compensation under Nasdaq's inducement grant exception. Specifically, the company granted non-statutory stock options to purchase a total of 1,380 shares and 6,260 RSUs. The options have an exercise price of $35.40 per share and will vest over a period of four years, contingent upon the employees' continued service. This initiative highlights PTC's efforts to boost its workforce and provide competitive compensation packages.
Price reaction · baseline $33.29 (2024-06-20 close) · hit after-hours · clean, no other PTCT news in the window
day 0 close · peak
+9.7%
day 1
+7.4%
day 3
+5.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • PTC Therapeutics is actively expanding its workforce by hiring new employees.
  • The inducement grants include stock options and RSUs, offering new hires a stake in the company's growth.
  • The strategic use of Nasdaq's inducement grant exception illustrates PTC's commitment to attracting talent.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+74%
120-day peak, hindsight
Typical move
6.6%
average across 4 past catalysts
Lead asset
Ataluren
Phase 3 · Cystic Fibrosis

Full Press Release Details

WARREN, N.J. , June 21, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on June 17, 2024 , the company approved non-statutory stock options to purchase an aggregate of 1,380 shares of its common stock and 6,260 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to nine new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
The inducement grants were approved by PTC's Compensation Committee on June 17, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of $35.40 per share, the closing price of PTC's common stock on June 17, 2024, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.
For more information please contact:

Frequently Asked Questions

What was the date of the stock option approval by PTC Therapeutics?

The stock options were approved on June 17, 2024.

How many new employees received stock options at PTC?

Nine new employees received stock options.

What is the exercise price for the stock options granted?

The exercise price is $35.40 per share.

How long is the vesting period for the stock options?

The stock options vest over four years.

What is the term duration for the stock options granted?

Each stock option has a term of 10 years.

Last updated: Jun 21, 2024